Business Television – Algernon Pharmaceuticals and the DMT/Stroke Clinical Program
Join Christopher J. Moreau, CEO of Algernon Pharmaceuticals as he discusses investigating the psychedelic drug DMT as a new potential treatment for Stroke. …
Streetwise Live! – Algernon is Awaiting Approval for a Phase 1 DMT Human Stroke Study
Listen to Cyndi Edwards, host of Streetwise Live!, speak with Algernon CEO Christopher J. Moreau, and ask two world-renowned psychedelic drug experts Professor David Nutt and Dr. Rick Strassman MD why DMT might work as a potential new stroke treatment. …
Proactive Investors Interview – Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy for DMT Intellectual Property
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the Company has disclosed that its intellectual property patent applications, filed in early 2021 for AP-188, included novel salt forms of DMT. Mr. Moreau explains that a novel salt form of a drug is a new and separate structure from the original compound and is considered a new composition of matter. Many drug compounds’ core structures can often be paired with a salt. Different salts can improve the core drug in several ways, including improved efficacy, safety/tolerability, and stability. …
Proactive Investors Interview – Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Stroke Study
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the Company has applied for a combined Clinical Trial and Ethics Approval application in the UK for a planned Phase 1 clinical human study of AP-188 or DMT in stroke patients. Mr. Moreau explains that the focus of this study is to investigate prolonged intravenous infusion of DMT, for durations that have never been clinically studied. This data, the company hopes, will help with its Phase 2 acute stroke and rehabilitation studies. …
This Pharmaceutical Company Has a Brilliant Concept – An Expert Opinion
Biotech is hard. It is full of failure and the frustrations of waiting, so it takes a lot for me to get excited about this sector. But I am beyond excited about one company that has found a conceptual loophole that puts its operations in a constant fast-forward or leapfrog mode, placing them heads above any other drug developers. Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE), and it remains one of only two pharmaceutical companies… View full story at: https://www.streetwisereports.com/article/2022/01/17/this-pharmaceutical-company-has-a-brilliant-concept.html …
Algernon Pharmaceuticals Ifenprodil Chronic Cough Study Receives Positive Feedback from U.S. FDA
Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news that the Company has received positive feedback from the U.S. Food and Drug Administration at their Pre-Investigational New Drug meeting regarding the use of Ifenprodil for the treatment of chronic cough. …
Streetwise Reports – Algernon Pharmaceuticals Looks to U.S. for Help Fighting Strokes
Algernon Pharmaceuticals Looks to U.S. for Help Fighting Strokes Canadian company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE) thinks investors in the United States will understand and support its mission to repurpose already approved drugs for new disease indications. The company listed on the Canadian Securities Exchange (CSE) has applied to list its common shares on the Nasdaq. Algernon Chief Executive Officer Christopher J. Moreau said he thinks Nasdaq investors may be more knowledgeable and experienced in the pharmaceutical sector and will be more interested in what the company has to offer. “The CSE is an excellent place for companies that …
Market One – Rethinking DMT: Algernon Pharmaceuticals’ Novel Approach to Stroke Treatment
The pharmaceutical industry is famous for its high R&D costs. But there are low-risk, capital-efficient alternatives to new drug development. Algernon Pharmaceuticals Inc. is exploring one such option: drug repurposing. Its current work includes research into microdoses of DMT as a treatment for acute stroke. Algernon CEO, Christopher J. Moreau, gives us some insight in this interview. View full interview transcript by clicking below: Rethinking DMT: Algernon Pharmaceuticals’ Novel Approach to Stroke Treatment …
Proactive Investors Interview – Algernon Pharmaceuticals Receives a Positive Response from U.S. FDA on SCLC Study
Algernon Pharmaceuticals CEO Christopher J. Moreau joins Steve Darling from Proactive to share news regarding the positive feedback from the U.S. Food and Drug Administration at their Investigational New Drug meeting for NP-120 or Ifenprodil for the treatment of small-cell lung cancer. Mr. Moreau explains that the feedback they received has led them to the decision to not plan any additional pre-clinical research and Algernon Pharmaceuticals will immediately move to file an application to begin a Phase 1 study as soon as possible. …
Upfront with Algernon Pharmaceuticals CEO Chistopher J Moreau – Episode 4
The interview series with Algernon Pharmaceuticals CEO Christopher Moreau and PRmediaNow host Cyndi Edwards continues. In today’s episode, Mr. Moreau discusses recent news regarding the Company’s positive feedback received on its Planned Phase 1/2a DMT Human Stroke Study. …
About Us
